Safe treatment of thiopurine S-methyltransferase deficient Crohn's disease patients with azathioprine
(2003) In Gut 52(1). p.140-142- Abstract
- Thiopurine S-methyltransferase (TPMT) deficient patients develop life threatening haematotoxicity (for example, pancytopenia) when treated with a standard dose of azathioprine (AZA) and 6-mercaptopurine (6-MP) due to excessive accumulation of cytotoxic metabolites. At present, it is generally recommended that these patients should not receive AZA or 6-MP treatment for inflammatory bowel disease. We report for the first time that Crohn's disease patients with TPMT deficiency can be successfully treated with AZA. We illustrate this with three cases where treatment has been successful and toxicity has been avoided by carefully titrating the drug dose. Thus very low TPMT activity demands pharmacogenetically guided dosing.
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/1126605
- author
- publishing date
- 2003
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Gut
- volume
- 52
- issue
- 1
- pages
- 140 - 142
- publisher
- BMJ Publishing Group
- external identifiers
-
- pmid:12477776
- scopus:0037214334
- ISSN
- 1468-3288
- DOI
- 10.1136/gut.52.1.140
- language
- English
- LU publication?
- no
- id
- da5063d1-7a97-4441-9daf-a085f0fb65fb (old id 1126605)
- date added to LUP
- 2016-04-01 16:28:54
- date last changed
- 2022-03-22 19:04:29
@article{da5063d1-7a97-4441-9daf-a085f0fb65fb, abstract = {{Thiopurine S-methyltransferase (TPMT) deficient patients develop life threatening haematotoxicity (for example, pancytopenia) when treated with a standard dose of azathioprine (AZA) and 6-mercaptopurine (6-MP) due to excessive accumulation of cytotoxic metabolites. At present, it is generally recommended that these patients should not receive AZA or 6-MP treatment for inflammatory bowel disease. We report for the first time that Crohn's disease patients with TPMT deficiency can be successfully treated with AZA. We illustrate this with three cases where treatment has been successful and toxicity has been avoided by carefully titrating the drug dose. Thus very low TPMT activity demands pharmacogenetically guided dosing.}}, author = {{Kaskas, B A and Louis, E and Hindorf, Ulf and Schaeffeler, E and Deflandre, J and Graepler, F and Schmiegelow, K and Gregor, M and Zanger, U M and Eichelbaum, M and Schwab, M}}, issn = {{1468-3288}}, language = {{eng}}, number = {{1}}, pages = {{140--142}}, publisher = {{BMJ Publishing Group}}, series = {{Gut}}, title = {{Safe treatment of thiopurine S-methyltransferase deficient Crohn's disease patients with azathioprine}}, url = {{http://dx.doi.org/10.1136/gut.52.1.140}}, doi = {{10.1136/gut.52.1.140}}, volume = {{52}}, year = {{2003}}, }